Diagnosis and management of ANCA associated vasculitis

BMJ (Online)

Volumn 344, Issue 7840, 2012, Pages

  Berden, Annelies ^a   Goc̈ȩrogľu, Arda ^a   Jayne, David ^b   Luqmani, Raashid ^c   Rasmussen, Niels ^d   Bruijn, Jan Anthonie ^a   Bajema, Ingeborg ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Statens Seruminstitut ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB;

ALOPECIA; AMENORRHEA; ANCA ASSOCIATED VASCULITIS; ANEMIA; BLADDER CANCER; BLOOD EXAMINATION; CATARACT; CHOLESTASIS; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CUSHINGOID SYNDROME; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ENCEPHALITIS; ENVIRONMENTAL FACTOR; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC CYSTITIS; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN DEFICIENCY; INCIDENCE; INFECTION; INFERTILITY; LEUKEMIA; LEUKOPENIA; LIVER DYSFUNCTION; MOUTH ULCER; NAUSEA; NEOPLASM; NEUTROPENIA; OSTEOPOROSIS; PLASMAPHERESIS; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SKIN ATROPHY; THROMBOCYTOPENIA; THRUSH; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; WEGENER GRANULOMATOSIS; WEIGHT GAIN;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; MEDICINE; PROGNOSIS;

EID: 84859002914     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e26     Document Type: Review

References (61)

1. Abdou NI, Kullman GJ, Hoffman GS, Sharp GC, Specks U, McDonald T, et al. Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 2002;29:309-16. (Pubitemid 34118779)
2. Watts RA, Scott DG, Jayne DR, Ito-Ihara T, Muso E, Fujimoto S, et al. Renal vasculitis in Japan and the UK - are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 2008;23:3928-31.
3. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000;43:414-9. (Pubitemid 30395752)
4. Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004;51:92-9. (Pubitemid 38222288)
5. Watts RA, Lane SE, Scott DG, Koldingsnes W, Nossent H, Gonzalez-Gay MA, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis 2001;60:1156-7.
6. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
7. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997;337:1512-23. (Pubitemid 27495778)
8. Reinhold-Keller E, Beuge N, Latza U, De GK, Rudert H, Nolle B, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-32. (Pubitemid 30368179)
9. Stone JH. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003;48:2299-309. (Pubitemid 36959212)
10. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9. (Pubitemid 41117433)
11. De Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
12. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44. (Pubitemid 36765101)
13. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8. (Pubitemid 47041083)
14. Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998;53:743-53. (Pubitemid 28124291)
15. Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999;111:507-13. (Pubitemid 29153147)
16. Arnold DF, Timms A, Luqmani R, Misbah SA. Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients. J Clin Pathol 2010;63:678-80.
17. McLaren JS, Stimson RH, McRorie ER, Coia JE, Luqmani RA. The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. QJM 2001;94:615-21. (Pubitemid 33100210)
18. Rasmussen N, Petersen J, Jensen H, Andersen V. Histopathological findings in biopsies from patients with Wegener's granulomatosis. APMIS Suppl 1990;19:15-6.
19. Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 2002;62:1732-42. (Pubitemid 35286281)
20. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). BMJ 1958;2:265-70.
21. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008;359:2790-803.
22. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, De GK, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-7.
23. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:23-32. (Pubitemid 26067088)
24. Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2011; published online 29 November.
25. Little MA, Nightingale P, Verburgh CA, Hauser T, De GK, Savage C, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036-43.
26. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
27. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
28. Walsh M, Catapano F, Szpirt W, Thorlund K, Bruchfeld A, Guillevin L, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 2011;57:566-74.
29. Bussel A, Jais JP. Side effects and mortality associated with plasma exchange: a three year experience with a regional register. Life Support Syst 1987;5:353-8.
30. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003;41:776-84. (Pubitemid 36396745)
31. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatol (Oxford) 2002;41:572-81. (Pubitemid 34567189)
32. Little MA, Nazar L, Farrington K. Outcome in glomerulonephritis due to systemic small vessel vasculitis: effect of functional status and non-vasculitic co-morbidity. Nephrol Dial Transplant 2004;19:356-64. (Pubitemid 38195984)
33. Slot MC, Tervaert JW, Franssen CF, Stegeman CA. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003;63:670-7. (Pubitemid 36126814)
34. Flossmann O, Berden A, De GK, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488-94.
35. Basu N, Jones GT, Fluck N, MacDonald AG, Pang D, Dospinescu P, et al. Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. Rheumatol (Oxford) 2010;49:1383-90.
36. Cotch MF. The socioeconomic impact of vasculitis. Curr Opin Rheumatol 2000;12:20-3. (Pubitemid 30036683)
37. De Leeuw K, Sanders JS, Stegeman C, Smit A, Kallenberg CG, Bijl M. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 2005;64:753-9. (Pubitemid 40559304)
38. Faurschou M, Mellemkjaer L, Sorensen IJ, Svalgaard TB, Dreyer L, Baslund B. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 2009;60:1187-92.
39. Heijl C, Harper L, Flossmann O, Stucker I, Scott DG, Watts RA, et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011;70:1415-21.
40. Morgan MD, Turnbull J, Selamet U, Kaur-Hayer M, Nightingale P, Ferro CJ, et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 2009;60:3493-500.
41. Suppiah R, Judge A, Batra R, Flossmann O, Harper L, Hoglund P, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 2011;63:588-96.
42. Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis JC Jr, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) study. Ann Intern Med 2005;142:620-6. (Pubitemid 40529958)
43. Stassen PM, Derks RP, Kallenberg CG, Stegeman CA. Venous thromboembolism in ANCA-associated vasculitis - incidence and risk factors. Rheumatol (Oxford) 2008;47:530-4.
44. Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2006;55:146-9. (Pubitemid 43235140)
45. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 2009;68:1827-32.
46. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8. (Pubitemid 24334817)
47. Luqmani RA, Exley AR, Kitas GD, Bacon PA. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol 1997;11:423-46. (Pubitemid 27296604)
48. Willcocks LC, Lyons PA, Rees AJ, Smith KG. The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis. Arthritis Res Ther 2010;12:202.
49. Knight A, Sandin S, Askling J. Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease. Arthritis Rheum 2008;58:302-7.
50. De Lind van Wijngaarden RA, van Rijn L, Hagen EC, Watts RA, Gregorini G, Tervaert JW et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol 2008;3:237-52.
51. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12-7. (Pubitemid 24011495)
52. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996;335:16-20. (Pubitemid 26230808)
53. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004;93:398-401. (Pubitemid 39382982)
54. Schlieben DJ, Korbet SM, Kimura RE, Schwartz MM, Lewis EJ. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 2005;45:758-61. (Pubitemid 40460764)
55. Silva F, Specks U, Sethi S, Irazabal MV, Fervenza FC. Successful pregnancy and delivery of a healthy newborn despite transplacental transfer of antimyeloperoxidase antibodies from a mother with microscopic polyangiitis. Am J Kidney Dis 2009;54:542-5.
56. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-63.
57. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990;87:4115-9. (Pubitemid 20217992)
58. Porges AJ, Redecha PB, Kimberly WT, Csernok E, Gross WL, Kimberly RP. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol 1994;153:1271-80.
59. Berden AE, Kallenberg CG, Savage CO, Yard BA, Abdulahad WH, de Heer E, et al. Cellular immunity in Wegener's granulomatosis: characterizing T lymphocytes. Arthritis Rheum 2009;60:1578-87.
60. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007;170:52-64. (Pubitemid 47339189)
61. Xing GQ, Chen M, Liu G, Heeringa P, Zhang JJ, Zheng X, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009;29:282-91.